Market research
ARQT Arcutis Biotherapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- 114.0
- Analyst target
- 36.875
- Dividend yield
- Not available
- Beta
- 1.53
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03969K1088
- Market cap
- 3B
- P/E ratio
- 114.0
- Analyst target
- 36.875
- Dividend yield
- Not available
- Beta
- 1.53
About
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ARQT discussion.
5 years, 4 months ago
Arcutis Biotherapeutics, Inc is currently in a long term downtrend where the price is trading 8.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Arcutis Biotherapeutics, Inc gets an overall score of 1/5.